Sagimet Biosciences Inc. Insider Trading
SGMT
Insiders sold $4.62M and bought nothing on the open market.
85% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Mar 2024.
Get an email when SGMT's executives or directors buy, or make a large sale outside a plan.
Trades · last 2 years
| Date | Insider | Trade | Shares | Price | Value | Of their stake | Filing |
|---|---|---|---|---|---|---|---|
| Aug 14 | George Kemble Director | Sold10b5-1 plan | 350,987 | $10.23 | $3.59M | 85% | Form 4 |
| Aug 11 | George Kemble Director | Sold10b5-1 plan | 20,206 | $9.95 | 201K | 25% | Form 4 |
| Jul 20 | David Happel President & CEO | SoldNo plan | 64,051 | $7.76 | 497K | 8.0% | Form 4 |
| Jul 20 | Elizabeth Rozek Chief Legal & Admin. Officer | SoldNo plan | 10,545 | $7.76 | 82K | 4.5% | Form 4 |
| Jul 20 | George Kemble Director | Sold10b5-1 plan | 18,844 | $7.46 | 141K | 23% | Form 4 |
| Feb 10 | David Happel President & CEO | SoldNo plan | 12,101 | $5.36 | 65K | 1.8% | Form 4 |
| Feb 10 | Thierry Chauche Chief Financial Officer | SoldNo plan | 1,312 | $5.36 | 7K | 7.7% | Form 4 |
| Feb 10 | Eduardo Bruno Martins Chief Medical Officer | SoldNo plan | 3,640 | $5.36 | 20K | 3.4% | Form 4 |
| Feb 10 | Elizabeth Rozek Chief Legal & Admin. Officer | SoldNo plan | 2,622 | $5.36 | 14K | 1.4% | Form 4 |
| Nov 20, 2025 | George Kemble Executive Chairman | Sold10b5-1 plan | 37,688 | $7.69 | 290K | 32% | Form 4 |
| Jul 21, 2025 | David Happel President & CEO | SoldNo plan | 65,478 | $9.13 | 598K | 8.7% | Form 4 |
| Jul 21, 2025 | Eduardo Bruno Martins Chief Medical Officer | SoldNo plan | 8,277 | $9.13 | 76K | 7.2% | Form 4 |
| Jul 21, 2025 | Elizabeth Rozek General Counsel and CCO | SoldNo plan | 10,780 | $9.13 | 98K | 5.5% | Form 4 |
- Aug 1410b5-1 planGeorge KembleDirector · sold 350,987 at $10.23$3.59M85% of stake
- Aug 1110b5-1 planGeorge KembleDirector · sold 20,206 at $9.95201K25% of stake
- Jul 20No planDavid HappelPresident & CEO · sold 64,051 at $7.76497K8.0% of stake
- Jul 20No planElizabeth RozekChief Legal & Admin. Officer · sold 10,545 at $7.7682K4.5% of stake
- Jul 2010b5-1 planGeorge KembleDirector · sold 18,844 at $7.46141K23% of stake
- Feb 10No planDavid HappelPresident & CEO · sold 12,101 at $5.3665K1.8% of stake
- Feb 10No planThierry ChaucheChief Financial Officer · sold 1,312 at $5.367K7.7% of stake
- Feb 10No planEduardo Bruno MartinsChief Medical Officer · sold 3,640 at $5.3620K3.4% of stake
- Feb 10No planElizabeth RozekChief Legal & Admin. Officer · sold 2,622 at $5.3614K1.4% of stake
- Nov 20, 202510b5-1 planGeorge KembleExecutive Chairman · sold 37,688 at $7.69290K32% of stake
- Jul 21, 2025No planDavid HappelPresident & CEO · sold 65,478 at $9.13598K8.7% of stake
- Jul 21, 2025No planEduardo Bruno MartinsChief Medical Officer · sold 8,277 at $9.1376K7.2% of stake
- Jul 21, 2025No planElizabeth RozekGeneral Counsel and CCO · sold 10,780 at $9.1398K5.5% of stake
Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.
Peers
Pharmaceutical Preparations · Pick stocks to compare with SGMT
Held by ETFs
SGMT is in 13 US ETFs. The largest of them, with SGMT's weight in each:
iShares Russell 2000 Growth ETFIWO0.03%of the fund
State Street SPDR S&P Biotech ETFXBI0.13%of the fund
iShares Biotechnology ETFIBB0.04%of the fund
Avantis U.S. Small Cap Equity ETFAVSC0.02%of the fund
Vanguard U.S. Momentum Factor ETFVFMO0.04%of the fund
Vanguard Russell 2000 Growth ETFVTWG0.03%of the fund
Spot a number that looks wrong? Check it in SGMT's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing SGMT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.